1.

Introduction
The majority of prostate cancer patients are diagnosed at a potentially curable stage and are often treated with radical prostatectomy or other first-line treatments [1] . However, a subset of patients with aggressive disease face the risk of prostate cancer recurrence, which can manifest as persistently elevated/increasing serum prostate-specific antigen or metastasis. Therefore, a critical goal in prostate cancer research is determining the molecular underpinnings of aggressive and indolent disease to improve patient management and prognosis. Recent studies demonstrated the utility of protein-coding genes as prognostic biomarkers [2, 3] . However, the lack of tissue specificity hinders the ability to monitor their expression levels noninvasively. In contrast, long noncoding RNAs (lncRNAs) are used successfully to diagnosis and risk stratify prostate cancer [4, 5] . Therefore, our study focuses on exploring lncRNAs as biomarkers for risk stratification to ultimately improve patient management.
Our group and others have leveraged next-generation sequencing to generate an unbiased transcriptome to discover novel lncRNAs in prostate cancer [6] [7] [8] . This has spurred numerous studies exploring the biological and clinical significance of lncRNAs [5, 9, 10] . However, to date, all of the transcriptome-based discoveries have utilized patient samples from high quality specimens (ie, abundance of tissue, snap frozen tissue, recently collected), which made them ideal to perform transcriptome sequencing but lacked longer-term clinical outcomes. To address this, we performed an integrative analysis of multiple independent transcriptome data collections [7, 11, 12] coupled with an unconventional microarray platform, with probe coverage of a significant portion of lncRNAs, to associate lncRNA expression with long-term outcomes such as metastasis, overall survival, and prostate-cancer specific mortality.
2.
Patients and methods
Clinical association of PCAT-14
Microarray data was obtained from four previously published datasets from the Decipher Genomic Resource Information Database [13] [14] [15] [16] . Data can also be found in the Gene Expression Omnibus: GSE29079, GSE46691, GSE62116, and GSE72291. Cancer versus normal analysis was performed in the pooled cohorts by Brase et al [13] . [17, 18] was obtained by training a logistic regression model with both variables, and the model predictions were compared with CAPRA-S alone [5] . Time-dependent receiver operating curves and the area under the curve was calculated using the ''timeROC'' R package (by Paul Blanche).
Multivariable analysis was performed using Cox regression stratified by cohort to adjust for baseline differences. Association of PCAT-14 with clinicopathologic variables was performed and statistical association with continuous variables was assessed using a Student t-test, and categorical variables with the chi-square test. All statistical tests were two-sided and significance was set as p < 0.05. Our study adheres to Reporting recommendations for tumor marker prognostic studies criteria [19] .
Results
Integrative lncRNA analysis
To identify consistently altered lncRNAs during prostate cancer progression, we performed an integrative analysis of three patient cohorts (Supplementary Table 1 ): (1) transcriptome sequencing of 14 primary tumors and matched adjacent normal tissue (Ren et al cohort) [7] , (2) transcriptome sequencing of 20 primary tumors and 10 matched adjacent normal tissues (Kannan et al cohort) [12] , and (3) Affymetrix gene expression of 131 primary and 19 metastatic tumors (Taylor et al cohort) [11] . Four lncRNAs were up-regulated and one lncRNA was down-regulated between the primary tumors and normal tissue across all three cohorts (Fig. 1A, Supplementary Tables 2-5) .
Leveraging the clinical data associated with the Taylor et al cohort [11] , we next assessed if the lncRNAs were associated with aggressive disease based on Gleason score. While multiple candidates are reported to have altered expression in prostate tumors (ie, DRAIC [9] , PCAT-14 [6] , PCAT-101 [6] ), PCAT-14 was the only lncRNA significantly down-regulated in patients with high (9) relative to low (6) Gleason scores (p = 0.00013; Fig. 1B progression ( Fig. 1C, Supplementary Fig. 1 ) as exemplified by PCAT-14 up-regulation in primary tumors compared with normal tissue (p = 1.3e-15) and PCAT-14 down-regulation in metastatic relative to primary tumors (p = 9.7e-06). Notably, PCAT-14 expression is enriched in prostate cancer as shown in our pan-cancer expression analysis of 6853 specimens across 18 additional solid tumors, as part of The Cancer Genome Atlas consortium ( Supplementary Fig.  2 ). This is further supported by a recent study reporting PCAT-14, under the gene alias PRCAT-104, to have altered expression specifically in prostate cancer [8] . Validation of PCAT-14 expression in a prostate cancer cell line panel relative to the control cell line, RWPE, confirmed overexpression of PCAT-14 in 22Rv1 and VCaP cell lines ( Supplementary Fig. 3A ). Subcellular localization revealed that PCAT-14 is enriched in the nucleus ( Supplementary Fig.  3B ), which is common amongst lncRNAs associated with gene regulation.
3.2.
Clinical significance of Given the altered expression of PCAT-14 in prostate cancer, we hypothesized a potential relationship with clinical outcomes. Therefore, we assessed PCAT-14 expression Table 1 ). The prognostic ability of PCAT-14 is significant even after accounting for clinicopathologic variables (age, prostate-specific antigen, Gleason, surgical Table 1 ). The Venn diagram shows the number of up-regulated (orange arrow) and down-regulated (blue arrow) DE lncRNAs identified in one to three datasets. Heatmaps of the normalized Affymetrix expression and normalized RNA-seq log fragments per kilobase of exon per million fragments mapped (FPKM) of the five DE lncRNAs from all three datasets are shown across normal, tumor, and metastatic samples in each datasets. Four of the five DE lncRNAs are up-regulated in the tumor dataset and one is down-regulated in all three datasets. Among these five lncRNAs, PCAT-14 is the only one that shows an association with tumor progression (Supplementary Table 2 margin status, seminal vesicle invasion, extracapsular extension, and lymph node invasion) on a pooled multivariable cox analysis (Table 2) Additionally, we investigated if PCAT-14 would improve the performance of an existing prediction algorithm, CAPRA-S. We found that when we added PCAT-14 to CAPRA-S, it increased the receiver operating characteristic area under the curve for 10-yr metastasis rates from 0.68 (CAPRA-S alone) to 0.70 (CAPRA-S + PCAT-14, p = 0.0185; Supplementary Fig. 4 ).
3.3.
High PCAT-14 expression promotes a less aggressive phenotype in vitro
To elucidate the mechanisms of PCAT-14 function, we utilized our large patient cohort to identify genes with correlated expression profiles to implicate PCAT-14 in various biological processes ( Supplementary Fig. 5 ). After ranking all genes according to their correlation value, we used Gene Set Enrichment Analysis [20] to search for enrichment across the Molecular Signatures Database [21] . We found an enrichment of Lys 27 of histone 3 methylated target genes among the highest ranked concepts, which were inversely correlated with PCAT-14 expression (Supplementary Fig. 5 ). Notably, EZH2 is overexpressed in metastatic prostate cancer, a marker of aggressive disease, and is a critical component of the polycomb repressive complex 2 that methylates Lys 27 of histone 3 to epigenetically silence target genes associated with metastasis and poor patient outcome [22] . Furthermore, we observed numerous signatures associated with tumor microenvironment that could also be indicative of aggressive disease ( Supplementary Fig. 5 CI = confidence interval; DMFS = distant metastasis-free survival; ECE = extracapsular extension; HR = hazard ratio; LNI = lymph node invasion; OS = overall survival; PCAT-14 = Prostate Cancer Associated Transcript-14; PCSS = prostate cancer-specific survival; PSA = prostate-specific antigen; SMS = surgical margin status; SVI = seminal vesical involvement. 0 1 7 ) 2 5 7 -2 6 6 less aggressive phenotypes. In vitro experiments measuring the mobility of cells overexpressing PCAT-14 show a decreased migratory/invasive capacity of these cells relative to the parental cell line with low PCAT-14 expression. PCAT-14 overexpressing IGR-Cap1 cells and empty vector control IGR-Cap1 cells were plated in serum-free media on a transwell membrane and allowed to migrate in a modified Boyden Chamber assay. After 24 h there was a significant 45% decrease in Clone 1 (p 0.00001) and 26% decrease in Clone 2 (p 0.001) in the migration of PCAT-14 overexpressing cells compared with control cells (Fig. 3A) . This decrease in migration was also seen in PC3 PCAT-14 overexpressing cells (Fig. 3B) . There was at least an 80% decrease in migrated cells in both PC3 PCAT-14 overexpressing cell lines compared with the control cell line (p 0.00001). Further, experiments were conducted with a Matrigel-coated transwell to further confirm altering PCAT-14 expression changes the aggressiveness of prostate cell lines. Similar to migration assays, PCAT-14 overexpression in both IGR-Cap1 and PC3 cells significantly diminished cellular invasion compared with the control cell lines ( Supplementary Fig. 6 ). Similarly, silencing PCAT-14 with a combination of small interfering RNAs (50% knockdown) in 22Rv1 cells with high endogenous expression resulted in a 137% (p 0.002) increase in migration relative to control transfected cells (Supplementary Fig. 7 ). The changes in migratory and invasive cellular behavior highlight that changes in expression levels of PCAT-14 in prostate cancer cause a less (high expression) or more (low expression) aggressive phenotype. Cellular proliferation was also monitored as an additional characterization of an aggressive phenotype. IGR-Cap1 cells overexpressing two different clones of PCAT-14 showed a 30% decrease in cell growth relative to control cells at Day 2 (p = 0.001 and p = 0.00001).
Time period (mo)
The diminished growth in PCAT-14-expressing cells continued to Day 6 with a 16% and 37% change in Clone 1 and Clone 2 cell growth, respectively ( Supplementary Fig. 8 ). Combined these data indicate that increased PCAT-14 expression diminishes oncogenic phenotypes in two well-studied aggressive prostate cancer cell lines; further, silencing PCAT-14 promotes an aggressive phenotype. Moreover, these data support the strong clinical observations that low PCAT-14 expression associates with aggressive disease.
PCAT-14 association with androgen deprivation therapy
Through Gene Set Enrichment Analysis, we also found that high PCAT-14 expression had a positive correlation with genes involved in prostate cancer ( Supplementary Fig. 5 ) and androgen response (Fig. 4A) . We also observed a moderate correlation (0.49) between PCAT-14 expression and androgen receptor transcriptional activity (Supplementary Fig. 9 ). Therefore, we investigated if PCAT-14 predicted the response to therapies such as androgen deprivation therapy (ADT) in the MCI and MCII cohorts. Of 780 patients, 236 underwent postoperative ADT within 1-yr of radical prostatectomy. We found that the distant metastasis-free survival prognostic differences between PCAT-14 high and low expression are increased in patients treated with ADT Figure 4B . As our cohorts are all retrospective, which confounds treatment by baseline risk, it is necessary to adjust for clinical and pathologic variables and other treatments such as radiotherapy. In our multivariate Cox model, which accounts for these confounders, we found statistically significant interaction terms for ADT and PCAT-14 (p = 0.029) indicating that PCAT-14 can potentially predict the response to ADT after prostatectomy (Supplementary Table 6 ). This is supported by PCAT-14 responsiveness to testosterone and R1881 in VCaP cells (Supplementary Fig.  10 ). After androgen deprivation, VCaP cells were treated with either 10 nM testosterone or 5 nM of R1881. There was a six-fold and approximately four-fold increase in PCAT-14 expression with testosterone and R1881 treatment, respectively, relative to no treatment control. As a positive control, there was also a robust increase in TMPRSS2 gene expression with both drug treatments.
Discussion
Our integrative analysis led us to discover a subset of lncRNAs consistently altered across prostate cancer patients suggesting their significance in prostate cancer etiology. Notably, the Ren et al cohort [7] is comprised of Chinese patients suggesting that these five lncRNAs are altered independent of ethnicity. The importance of these lncRNAs is exemplified by a recent study showing that DRAIC plays a tumor-suppressive role, displays decreased expression in prostate cancer cell progression from androgen-dependent to a castration-resistant state, and inhibits cellular migration and invasion [9] . Less is known about the remaining candidates that were only recently discovered and reported to have altered expression during prostate tumorigenesis [6, 8] or are not yet associated with prostate cancer (ie, LOC283177). However, PCAT-14 was the only candidate that showed an inverse relationship with Gleason score suggestive of its role in suppressing aggressive disease, and therefore represents an ideal candidate to investigate. Herein, we show that PCAT-14 is overexpressed in prostate tumors and that lower PCAT-14 expression associates with three clinical endpoints (distant metastasis-free survival, prostate cancer specific survival, and overall survival). Supporting our clinical findings, we have provided experimental data highlighting the biological role of PCAT-14 in prostate cancer. Firstly, using patient data we were able to associate low PCAT-14 expression with biological concepts associated with aggressive disease. Secondly, we demonstrated that PCAT-14 suppresses metastatic phenotypes in vitro and appears to lose expression in metastatic samples. Stably overexpressing PCAT-14 in both IGR-Cap1 and PC3 cells resulted in significantly less cellular mobility relative to respective control cell lines. Moreover, the opposite effect-a more oncogenic phenotype-was observed in PCAT-14 silenced 22Rv1 cells. Taken together, this represents the first study highlighting the biological significance of PCAT-14 in prostate cancer as well as the clinical significance of low PCAT-14 expression for predicting outcome.
Notably, we observed that patients who received ADT appeared to have a greater distant metastasis-free survival prognostic difference between PCAT-14 high and low expression in comparison to patients that did not receive ADT. As these are retrospective studies, there are inherent differences between patients that received treatment and those that did not receive treatment. However, our multivariate interaction analysis coupled with the in vitro data demonstrating that PCAT-14 is androgen responsive suggests that PCAT-14 warrants further study as a predictive marker for ADT response.
Conclusions
Overall, we discovered that PCAT-14 is commonly upregulated in primary tumors. Furthermore, low PCAT-14 expression promotes aggressive oncogenic phenotypes and is significantly prognostic for multiple clinical endpoints. In addition to predicting metastatic disease, we found that PCAT-14 may be able to predict ADT response highlighting its potential use for improving patient management and prognosis.
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